NASDAQ:MDGL Madrigal Pharmaceuticals (MDGL) Stock Price, News & Analysis $438.16 +0.42 (+0.10%) As of 02:33 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Madrigal Pharmaceuticals Stock (NASDAQ:MDGL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MDGL alerts:Sign Up Key Stats Today's Range$433.89▼$444.8350-Day Range$434.24▼$546.9352-Week Range$393.61▼$615.00Volume98,652 shsAverage Volume329,339 shsMarket Capitalization$10.12 billionP/E RatioN/ADividend YieldN/APrice Target$699.20Consensus RatingModerate Buy Company Overview Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for nonalcoholic steatohepatitis, now known as metabolic dysfunction-associated steatohepatitis (MASH), and other chronic liver diseases. The company is headquartered in West Conshohocken, Pennsylvania. Madrigal’s lead product is Rezdiffra (resmetirom), an orally administered thyroid hormone receptor beta agonist designed to target key drivers of liver disease, including hepatic fat accumulation and fibrosis. In March 2024, the U.S. Food and Drug Administration approved Rezdiffra, in combination with diet and exercise, for adults with noncirrhotic MASH and moderate to advanced liver fibrosis. The company’s activities include the commercialization of Rezdiffra in the United States, as well as ongoing research and development related to MASH and associated liver conditions. Madrigal is led by Chief Executive Officer Paul A. Friedman, with Rebecca Taub serving as president and chief medical officer.AI Generated. May Contain Errors. Read More Madrigal Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreMDGL MarketRank™: 3.54694774961 of 5 starsMadrigal Pharmaceuticals scored higher than 71% of companies evaluated by MarketBeat, and ranked 321st out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingMadrigal Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on no strong buy ratings, 15 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialMadrigal Pharmaceuticals has a consensus price target of $699.20, representing about 57.9% upside from its current price of $442.85.Amount of Analyst CoverageMadrigal Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Madrigal Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Madrigal Pharmaceuticals are expected to grow in the coming year, from ($7.03) to $5.30 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Madrigal Pharmaceuticals is -34.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Madrigal Pharmaceuticals is -34.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMadrigal Pharmaceuticals has a P/B Ratio of 16.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Madrigal Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted11.53% of the float of Madrigal Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverMadrigal Pharmaceuticals has a short interest ratio ("days to cover") of 7.24.Change versus previous monthShort interest in Madrigal Pharmaceuticals has recently decreased by 8.42%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMadrigal Pharmaceuticals does not currently pay a dividend.Dividend GrowthMadrigal Pharmaceuticals does not have a long track record of dividend growth. News and Social Media1.5 / 5News Sentiment0.46 News SentimentMadrigal Pharmaceuticals has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Madrigal Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 1 people have searched for MDGL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Madrigal Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Madrigal Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,581,182.00 in company stock.Percentage Held by Insiders17.60% of the stock of Madrigal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions98.50% of the stock of Madrigal Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Madrigal Pharmaceuticals' insider trading history. Receive MDGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MDGL Stock News HeadlinesMadrigal to Present Multiple Abstracts at AASLD's The Liver Meeting 2026, Including New Real-World Evidence Reinforcing Rezdiffra as a Foundational Therapy for MASHOctober 27 at 8:00 AM | globenewswire.comCritical Contrast: Madrigal Pharmaceuticals (NASDAQ:MDGL) & Incyte (NASDAQ:INCY)October 25 at 4:29 AM | americanbankingnews.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.October 27 at 1:00 AM | Weiss Ratings (Ad)Madrigal Pharmaceuticals: The Market Is Grading A Launch, Not A Self-Funding FranchiseOctober 20, 2026 | seekingalpha.comMadrigal Pharmaceuticals to Release Third-Quarter 2026 Financial Results and Host Webcast on November 3, 2026October 20, 2026 | globenewswire.comMadrigal Pharmaceuticals, Inc. (MDGL) - What Are Investment Firms Thinking About This Stock?October 20, 2026 | americanbankingnews.comBofA Securities Adjusts Price Target on Madrigal Pharmaceuticals to $533 From $543, Maintains Neutral RatingOctober 19, 2026 | marketscreener.comMMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)October 15, 2026 | globenewswire.comSee More Headlines MDGL Stock Analysis - Frequently Asked Questions How have MDGL shares performed this year? Madrigal Pharmaceuticals' stock was trading at $582.34 on January 1st, 2026. Since then, MDGL shares have decreased by 24.0% and is now trading at $442.8540. How were Madrigal Pharmaceuticals' earnings last quarter? Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) posted its quarterly earnings data on Thursday, July, 30th. The biopharmaceutical company reported ($1.99) earnings per share for the quarter, beating the consensus estimate of ($2.68) by $0.69. The business's quarterly revenue was up 71.2% compared to the same quarter last year. Read the conference call transcript. Who are Madrigal Pharmaceuticals' major shareholders? Madrigal Pharmaceuticals' top institutional investors include EULAV Asset Management (0.22%), Assenagon Asset Management S.A. (0.09%), NFSG Corp (0.01%) and Sivik Global Healthcare LLC (0.01%). Insiders that own company stock include Bros Advisors Lp Baker, Rebecca Taub, William John Sibold, Paul A Friedman, Richard S Levy, Brian Joseph Lynch, Carole Huntsman, Mardi Dier, Shannon T Kelley, Fred B Craves, David Soergel, Robert E Waltermire, Kenneth Bate and James M Daly. View institutional ownership trends. How do I buy shares of Madrigal Pharmaceuticals? Shares of MDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Madrigal Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Madrigal Pharmaceuticals investors own include Viking Therapeutics (VKTX), NVIDIA (NVDA), Advanced Micro Devices (AMD), Exelixis (EXEL), Tesla (TSLA), Incyte (INCY) and Intel (INTC). Company Calendar Last Earnings7/30/2026Today10/27/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 As of 4 days ago, MDGL's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:MDGL CIK1157601 Webwww.madrigalpharma.com Phone(267) 824-2827Fax781-274-8228Employees915Year Founded2011Price Target and Rating Average Price Target for Madrigal Pharmaceuticals$699.20 High Price Target$962.00 Low Price Target$542.00 Potential Upside/Downside+59.2%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage18 Analysts Profitability EPS (Trailing Twelve Months)($12.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$288.28 million Net Margins-25.32% Pretax Margin-25.32% Return on Equity-56.65% Return on Assets-25.53% Debt Debt-to-Equity Ratio0.65 Current Ratio3.20 Quick Ratio2.94 Sales & Book Value Annual Sales$1.28 billion Price / Sales7.90 Cash FlowN/A Price / Cash FlowN/A Book Value$26.54 per share Price / Book16.55Miscellaneous Outstanding Shares23,104,000Free Float19,038,000Market Cap$10.15 billion OptionableOptionable Beta-1.04 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:MDGL) was last updated on 10/27/2026 by MarketBeat.com Staff. From Our PartnersU.S. Military Expands Orders for This Drone MakerA Nasdaq-listed drone maker is racking up defense contracts on both sides of the border. The Canadian Armed Fo...The Tomorrow Investor | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredFirst Look: Elon’s “Starphone”Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Madrigal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Madrigal Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
